Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q3 FY20 results · Oct–Dec 2019
Lincoln Pharmaceuticals reported revenue from operations of ₹95.64 crore (up 18.1% from Q3 FY19) and net profit of ₹10.18 crore (up 7.7% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a standalone basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 95.64 | 81.00 | +18.1% | 110.60 | −13.5% |
| Other income | 2.37 | 0.53 | +342.5% | 2.88 | −17.7% |
| Total income | 98.01 | 81.54 | +20.2% | 113.47 | −13.6% |
| Profit before tax | 12.05 | 11.27 | +6.9% | 23.62 | −49.0% |
| Net profit for the period | 10.18 | 9.45 | +7.7% | 17.99 | −43.4% |
| EPS, basic (₹) | 5.09 | 4.73 | +7.6% | 8.99 | −43.4% |
| Net margin (%) | 10.6 | 11.7 | 16.3 |
Standalone
- Filed with BSE
- 14 Feb 2020, 14:47 IST
- Board meeting
- 13 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE